Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1).

T Fryatt, HI Pettersson, WT Gardipee, KC Bray, SJ Green, Alexandra Martha Zoya Slawin, HD Beall, CJ Moody

Research output: Other contribution

59 Citations (Scopus)

Abstract

A series of quinolinequinones bearing various substituents has been synthesized, and the effects of substituents on the metabolism of the quinones by recombinant human NAD(P)H:quinone oxidoreductase (hNQO1) was studied. A range of quinolinequinones were selected for study, and were specifically designed to probe the effects of aryl substituents at C-2. A range of 28 quinolinequinones 2-29 was prepared using three general strategies: the palladium(0) catalyzed coupling of 2-chloroquinolines, the classical Friedlander synthesis and the double-Vilsmeier reaction of acetanilides. One example of an isoquinolinequinone 30 was also prepared, and the reduction potentials of the quinones were measured by cyclic voltammetry. For simple substituents R-2 at the quinoline 2-position, the rates of quinone metabolism by hNQO1 decrease for R-2 = Cl>Hsimilar toMe>Ph. For aromatic substituents, the rate of reduction decreases dramatically for R-2 = Ph > 1-naphthyl > 2-naphthyl > 4-biphenyl. Compounds containing a pyridine substituent are the best substrates, and the rates decrease as R-2 4-pyridyl > 3-pyridyl > 2-pyridyl > 4-methyl-2-pyridyl > 5-methyl-2-pyridyl. The toxicity toward human colon carcinoma cells with either no detectable activity (H596 or BE-WT) or high NQO1 activity (H460 or BE-NQ) was also studied in representative quinones. Quinones that are good substrates for hNQO1 are more toxic to the NQO1 containing or expressing cell lines (H460 and BE-NQ) than the NQO1 deficient cell lines (H596 and BE-WT). (C) 2004 Elsevier Ltd. All rights reserved.

Original languageEnglish
Volume12
DOIs
Publication statusPublished - 1 Apr 2004

Keywords

  • HUMAN DT-DIAPHORASE
  • HUMAN TUMOR-CELLS
  • BIOREDUCTIVE ANTICANCER AGENTS
  • ANTIBIOTIC STREPTONIGRIN
  • RECOMBINANT HUMAN
  • DRUG DEVELOPMENT
  • IN-VITRO
  • QUINONE OXIDOREDUCTASE-1
  • MITOMYCIN-C
  • EC 1.6.99.2

Fingerprint

Dive into the research topics of 'Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1).'. Together they form a unique fingerprint.

Cite this